North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
NCT04906213
Recruiting
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2
Register for Updates
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
NCT06852976
Recruiting
The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2025
Locations: Site 001, Durham, North Carolina
Conditions: Diabetic Foot Ulcer
Register for Updates
A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM
NCT06167655
Recruiting
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: Queen City Clinical Research, Charlotte, North Carolina
Conditions: Headache Migraine Chronic
Register for Updates
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220
Recruiting
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL). This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be improved. Ritu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 15, Durham, North Carolina
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
Accelerated TMS for Focal Hand Dystonia
NCT06015672
Recruiting
This study aims to investigate the impact of accelerated transcranial magnetic stimulation (TMS) on brain function and behavior in patients with focal hand dystonia. Previous research demonstrated that individualized TMS improved dystonic behavior after one session. Building on this, the current study administers four TMS sessions in a day, with assessments conducted in four weeks, twelve weeks, and 20 weeks after each session. The research involves 8 in-person and 6 virtual visits focused on fu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Isolated Focal Hand Dystonia
Register for Updates
Real World Registry for Use of the Ion Endoluminal System
NCT06004440
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Atrium Health of the Carolinas, Charlotte, North Carolina
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
Register for Updates
Take A Break - Rural
NCT05790486
Recruiting
The study team proposes a multi-level trial to test 1) novel implementation programs in rural counties designed to increase access to 2) recent advances in tobacco control services for people who are not-yet-ready-to-quit smoking. In this field, most trials have focused only on those already ready-to-quit. Thus, the proposed trial addresses an important knowledge gap critical to advance tobacco control in rural areas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Smoking, Smoking Behaviors, Smoking Cessation
Register for Updates
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342
Recruiting
This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer. How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to us... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Levine Cancer Institute /ID# 242851, Charlotte, North Carolina
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284
Recruiting
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/03/2025
Locations: Wake Forest University, Winston-Salem, North Carolina
Conditions: Glioblastoma Multiforme
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Duke University, Durham, North Carolina
Conditions: Partial Epilepsy
Register for Updates